Viewing data from:

IZERVAY

NDA

AVACINCAPTAD PEGOL SODIUM | N217225 | ASTELLAS PHARMA US INC

1 strength6 unique patents0 unique exclusivities

Patent Timeline

6 unique patents by expiration date

Expiring < 1yr (3)Active (3)Today

2027

2028

2029

2030

2031

2032

2033

2034

Today

Feb. 14, 2027

Nov. 11, 2026

Feb. 14, 2027

Jul. 11, 2034

Jul. 11, 2034

Jul. 11, 2034

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Izervay (2023)

Total Spending

$216K

Total Claims

Beneficiaries

Avg Cost/Unit

$22040.88

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Mar 6, 2026	SUPPL -4	View Letter (PDF)
Feb 13, 2025	SUPPL -1	View Letter (PDF)
Aug 7, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)

RLD

6 patents0 exclusivities▴

SOLUTION;INTRAVITREAL | Approved: Aug 4, 2023

Patents (6)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7579456	Feb 14, 2027	—	Yes	—	—	—
8236773	Nov 11, 2026	—	—	—		—
9617546	Feb 14, 2027	—	Yes	—		—
11273171	Jul 11, 2034	—	—	—		—
11491176	Jul 11, 2034	—	—	—		—
12016875	Jul 11, 2034	—	—	—		—